In light of the U.S. pharmaceutical market’s evolving landscape under President Trump’s administration, we sought insights from GV Prasad, Co-Chairman and Managing Director of Dr. Reddy’s Laboratories. Addressing the anticipated impacts of U.S. trade policy changes and the strategic adjustments necessitated by global trade dynamics, Prasad provides a nuanced view of the challenges and opportunities ahead for Indian pharmaceutical companies. His responses underscore the competitive nature of the U.S. generics market and highlight strategic moves to enhance supply chain resilience in response to shifting sentiments towards key suppliers like China.
With Donald Trump taking office and the potential for significant changes in U.S. trade policies, how do you anticipate these changes will impact the Indian pharmaceutical industry, particularly in terms of market access and regulatory challenges for exporting generics to the U.S.?
I do not see any major shift in the business environment for Indian pharmaceutical companies in the USA. The generics market in the USA is already highly competitive and hence tariffs and localization initiatives are unlikely to make a measurable impact on competition. Since India is primarily in generics with very limited presence in innovation, I do not foresee any major impacts from policy changes under the Trump administration.
Considering the Trump administration’s focus on reshaping global trade dynamics, especially with key suppliers like China, what strategic adjustments is your company considering to mitigate risks and capitalize on potential trade shifts? How do you plan to enhance your supply chain resilience to maintain a steady supply of APIs and finished products to the U.S. market?
Indian CDMO’s and CRO’s are already seeing increasing traction for their business from USA as a result of the Biosecure act. While the act itself did not pass the senate, the negative US sentiment towards China is driving more opportunities to India. However China has made giant strides in innovation and has emerged as a leading biopharmaceutical innovator and this is going to power their global growth aided by favourable government support and a vibrant local market. Already China ranks second in terms of innovation next only to the USA.
We continue to have a global supply chain with increasing reliance on local Indian producers and vertical integration. We also believe China will remain a major supplier of key materials and we will need to be interdependent on each other. China will remain a major supplier and our own exports to China will also increase. We do not see any major shift in the near term but we will watch how the policies evolve.
